A new clinical trial involving IBI3042 was registered on September 25, 2026. The study, titled "A Study of IBI3042 in Healthy Adult Participants," is listed under identifier NCT07842393.
According to the registry entry, the trial is a Phase 1 study. Its current status is listed as not yet recruiting as of the date above. No enrollment numbers, dosing details, or outcome data are included in this update.
The trial record does not specify further design details beyond its phase and participant population, described as healthy adult participants. As the study has not yet begun recruiting, no results or safety findings have been reported at this stage.
This entry reflects a registration update only and does not indicate any findings about efficacy or safety. Readers interested in tracking this study can consult the official registry listing for updates on recruitment status and future results postings.
For more background on glucagon as a compound, readers can consult the compound overview page.